Gulden debutes the Rowe OCT Model Eye

Article

Gulden Ophthalmics recently introduced Rowe OCT Model Eye, a solid-state tissue phantom that is used by clamping it to an instrument and initiating an OCT test.

Elkins Park, PA-Gulden Ophthalmics recently introduced Rowe OCT Model Eye, a solid-state tissue phantom that is used by clamping it to an instrument and initiating an OCT test. It eliminates the need to use staff members or patients to check, practice, and use OCT equipment. Because it produces a standard test result based on a normal macula it provides a stabile, long-term benchmark for OCT instruments.

Imaging a choroidal nevus

According to the company, OCT Model Eye can be used for system demonstrations and tests; staff education, instruction, and practice; OCT instrument research and development; and as a standard for multi-instrument DME trials at several sites.            

The OCT Model Eye features a realistic, six-layer retina 300 um thick, 4.8 mm in diameter; a 120 um deep foveal pit; photoreceptor inner segment (IS)/outer segment (OS)/retinal pigment epithelium (RPE) layer with choroidal transition. It is fluid free and easy to image with a large 12.6 mm cornea and 8 mm diameter pupil and is 23.5 mm in axial length.  Images using the OCT Model Eye exhibit clear layer structure, foveal pit, and IS/OS/RPE layer.

The OCT Model Eye is provided and stored in a wooden case with instructions, an attachment rod for mounting on an ophthalmic instrument chin rest, and a mounting clamp.

Laser injury requires second opinion

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Rachelle Lin, OD, MS, FAAO, on collaborating more effectively on neovascular retinal cases
Susana Marcos, PhD, discusses the implications her research presents for the role optical coherence tomography (OCT) could play in presbyopia and myopia accommodation efforts.
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Rachelle Lin, OD, MS, FAAO
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
© 2025 MJH Life Sciences

All rights reserved.